Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4.48%21.75B | 2.91%14.66B | 2.93%6.7B | -12.24%32.47B | -15.48%20.81B | -14.33%14.25B | -13.10%6.51B | -7.96%37B | -8.60%24.63B | -9.52%16.63B |
| Special items of operating revenue | -25.20%94M | -20.78%64.92M | -12.90%33.14M | 100.27%170.61M | 118.50%125.67M | 146.72%81.95M | 204.98%38.05M | 419.25%85.19M | --57.51M | --33.22M |
| Operating income | 4.31%21.84B | 2.77%14.73B | 2.84%6.73B | -11.98%32.64B | -15.17%20.94B | -14.00%14.33B | -12.74%6.55B | -7.79%37.09B | -8.39%24.68B | -9.34%16.67B |
| Operating expenses | -6.99%-15.57B | -3.64%-10.45B | -3.19%-4.88B | 16.48%-22.99B | 20.84%-14.56B | 19.24%-10.08B | 18.42%-4.73B | 10.30%-27.52B | 11.74%-18.39B | 11.60%-12.48B |
| Gross profit | -1.82%6.27B | 0.73%4.28B | 1.93%1.86B | 0.96%9.66B | 1.39%6.38B | 1.62%4.25B | 6.49%1.82B | 0.29%9.57B | 3.03%6.3B | -1.85%4.18B |
| Selling expenses | 8.16%-503.09M | 4.46%-332.21M | 5.65%-164.41M | -0.90%-851.58M | 1.07%-547.81M | -1.37%-347.73M | -2.25%-174.26M | -3.93%-844M | -8.29%-553.72M | -10.22%-343.04M |
| Administrative expenses | 0.74%-1.46B | -0.56%-961.29M | -0.49%-490.57M | -2.27%-2.39B | -0.55%-1.47B | 1.47%-955.97M | -5.38%-488.17M | -2.00%-2.34B | 1.91%-1.46B | -1.55%-970.23M |
| Research and development expenses | -9.89%-1.28B | -6.99%-802.86M | -0.89%-379.61M | -2.69%-1.91B | -6.89%-1.16B | -15.68%-750.41M | -22.98%-376.27M | -10.21%-1.86B | -0.53%-1.09B | -0.02%-648.67M |
| Profit from asset sales | -105.71%-2.43M | -1,182.25%-485.24K | -35.42%-438.97K | 66,149.68%42.2M | 32,192.95%42.52M | -116.40%-37.84K | -766.67%-324.16K | -99.78%63.7K | -99.56%131.66K | -99.14%230.7K |
| Impairment and provision | 34.76%-86.66M | 55.23%-37.18M | -106.51%-4.57M | 24.99%-346.22M | -40.07%-132.82M | -10.11%-83.05M | 163.68%70.15M | 17.15%-461.56M | 30.67%-94.83M | 31.04%-75.42M |
| -Other impairment is provision | 34.76%-86.66M | 55.23%-37.18M | -106.51%-4.57M | 24.99%-346.22M | -40.07%-132.82M | -10.11%-83.05M | 163.68%70.15M | 17.15%-461.56M | 30.67%-94.83M | 31.04%-75.42M |
| Operating interest expense | 72.58%-2.89M | 62.35%-2.07M | -4.13%-1.42M | -1,910.81%-14.72M | -2,084.50%-10.54M | -3,704.17%-5.5M | ---1.36M | ---732.17K | ---482.39K | ---144.56K |
| Special items of operating profit | 19.10%339.76M | 24.11%226.12M | -18.62%47.61M | -1.67%546.3M | -25.08%285.27M | -38.96%182.19M | -51.73%58.5M | 13.75%555.59M | -4.04%380.75M | -6.79%298.49M |
| Operating profit | -3.67%3.11B | 3.46%2.25B | -6.26%801.82M | 2.07%4.45B | -3.14%3.23B | -7.00%2.17B | -2.71%855.37M | -2.37%4.36B | 5.04%3.33B | -5.40%2.34B |
| Financing cost | -62.79%20.33M | -64.80%27.94M | -27.21%17.69M | -21.26%236.41M | -72.85%54.63M | -44.62%79.37M | -57.08%24.3M | 26.15%300.23M | -39.03%201.2M | -23.68%143.31M |
| Adjustment items of earning before tax | -63.01%8.1M | -26.01%6.36M | -47.07%3.72M | 47.04%43.29M | 54.90%21.9M | -14.97%8.59M | 54.60%7.02M | -23.33%29.44M | -44.65%14.14M | -2.46%10.1M |
| Earning before tax | -5.04%3.14B | 0.96%2.28B | -7.16%823.22M | 0.86%4.73B | -6.86%3.3B | -9.20%2.26B | -5.71%886.7M | -1.11%4.69B | 0.55%3.55B | -6.67%2.49B |
| Tax | 13.10%-503.92M | -4.76%-422.4M | 1.72%-170.92M | 2.02%-661.84M | 2.45%-579.88M | -5.22%-403.21M | -6.21%-173.91M | -5.20%-675.45M | -2.88%-594.43M | 19.71%-383.19M |
| After-tax profit from continuing operations | -3.33%2.63B | 0.13%1.86B | -8.49%652.3M | 1.35%4.07B | -7.75%2.72B | -11.82%1.86B | -8.22%712.79M | -2.09%4.01B | 0.10%2.95B | -3.83%2.11B |
| Earning after tax | -3.33%2.63B | 0.13%1.86B | -8.49%652.3M | 1.35%4.07B | -7.75%2.72B | -11.82%1.86B | -8.22%712.79M | -2.09%4.01B | 0.10%2.95B | -3.83%2.11B |
| Minority profit | -4.43%347.75M | -7.30%241.26M | -16.32%90.62M | 6.83%574.22M | -5.51%363.87M | -8.60%260.26M | 9.73%108.3M | 15.10%537.51M | 10.95%385.08M | 10.15%284.74M |
| Profit attributable to shareholders | -3.16%2.28B | 1.34%1.62B | -7.08%561.68M | 0.50%3.49B | -8.09%2.36B | -12.32%1.6B | -10.84%604.49M | -4.30%3.48B | -1.35%2.57B | -5.70%1.82B |
| Basic earnings per share | 0.00%0.22 | 0.00%0.15 | -16.67%0.05 | 0.00%0.32 | -8.33%0.22 | -11.76%0.15 | 0.00%0.06 | -3.03%0.32 | -4.00%0.24 | -5.56%0.17 |
| Diluted earnings per share | 0.00%0.22 | 0.00%0.15 | -16.67%0.05 | 0.00%0.32 | -8.33%0.22 | -11.76%0.15 | 0.00%0.06 | -3.03%0.32 | -4.00%0.24 | -5.56%0.17 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.